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Abstract
Background: RNA processing plays a critical role in the replication of HIV-1, regulated in part through the action
of host SR proteins. To explore the impact of modulating SR protein activity on virus replication, the effect of
increasing or inhibiting the activity of the Cdc2-like kinase (CLK) family of SR protein kinases on HIV-1 expression
and RNA processing was examined.
Results: Despite their high homology, increasing individual CLK expression had distinct effects on HIV-1, CLK1
enhancing Gag production while CLK2 inhibited the virus. Parallel studies on the anti-HIV-1 activity of CLK
inhibitors revealed a similar discrepant effect on HIV-1 expression. TG003, an inhibitor of CLK1, 2 and 4, had no
effect on viral Gag synthesis while chlorhexidine, a CLK2, 3 and 4 inhibitor, blocked virus production. Chlorhexidine
treatment altered viral RNA processing, decreasing levels of unspliced and single spliced viral RNAs, and reduced
Rev accumulation. Subsequent experiments in the context of HIV-1 replication in PBMCs confirmed the capacity of
chlorhexidine to suppress virus replication.
Conclusions: Together, these findings establish that HIV-1 RNA processing can be targeted to suppress virus
replication as demonstrated by manipulating individual CLK function and identified chlorhexidine as a lead
compound in the development of novel anti-viral therapies.
Background
The dependence of HIV-1 replication on the appropriate
balance of its RNA processing suggests that this step in
the virus lifecycle might be an attractive target for thera-
peutic intervention [1-3]. From a single 9 kb transcript,
over 40 mRNAs are generated by a process of subopti-
mal splicing that generates three classes of HIV-1
mRNAs: unspliced (US) RNA used to produce Gag and
Gagpol proteins; singly spliced (SS) mRNAs encoding
Vif, Vpr, Vpu or Env; and multiply spliced (MS)
mRNAs used to synthesize Rev, Tat or Nef. Both Tat
and Rev play central roles in the replication of HIV-1.
Tat increases abundance of all viral RNAs by increasing
elongation efficiency of RNA polymerase II on proviral
DNA [4,5] while Rev promotes the transport of
unspliced and singly spliced viral RNAs to the cytoplasm
[6,7]. Consequently, factors which alter the extent of
HIV-1 RNA splicing can have dramatic effects on the
extent of viral replication; undersplicing resulting in the
loss of Tat and Rev while oversplicing reduces the abun-
dance of incompletely spliced RNAs so that there is
insufficient Gag and Env protein for new virion assem-
bly. Understanding how to manipulate conditions within
the cell to alter the extent of HIV-1 RNA splicing could
provide insights into new strategies to control this
infection.
Studies to date have identified a number of cis- and
trans-acting factors involved in regulating HIV-1 RNA
splicing [1,2]. Examination of the four splice donors and
eight splice acceptors, used in generating the complete
spectrum of viral mRNAs, demonstrated that much of
the regulation is due to the suboptimal nature of the
sequences that comprise the 3’ splice sites (3’ss). Muta-
tions that optimize the splice sites result in dramatic
* Correspondence: alan.cochrane@utoronto.ca
2Dept. of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
Full list of author information is available at the end of the article
Wong et al. Retrovirology 2011, 8:47
http://www.retrovirology.com/content/8/1/47
© 2011 Wong et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.shifts in usage, increasing the extent of viral RNA spli-
cing and reducing HIV-1 replication [8,9]. Use of speci-
fic 3’ss is also regulated by the presence of exon splicing
silencers (ESSs) and exon splicing enhancers (ESEs) that
act in an antagonistic fashion to suppress or promote,
respectively, the use of particular splice sites. The major-
ity of HIV-1 ESSs function by binding of hnRNP A1,
which promotes addition of further hnRNP A1 mole-
cules to adjacent sequences and thereby sterically blocks
interaction of U2 snRNP and U2AF with the branch-
point and polypyrimidine tract [10-14]. The ESEs coun-
ter the ESSs by the binding of specific members of the
SR protein family. SR proteins consist of one or two N-
terminal RNA binding motifs and a C-terminus rich in
arginine-serine dipeptides which collaborate to promote
the use of adjacent splice sites by stabilizing interaction
of splicing factors (such as U2AF, U1 snRNP) with the
splice site signals [15]. In some instances, binding to an
ESE also occludes interaction of factors with the adja-
cent/overlapping ESS [13,16]. The significance of these
factors in regulating HIV-1 RNA processing has been
illustrated by examining the effect of mutating the cis
elements in viral RNA or altering SR protein expression
levels in cells. Mutations which inactivate the ESS near
the vpr reading frame (ESSV) resulted in both a signifi-
cant increase in use of the adjacent 3’ splice site (splice
acceptor 2, SA2) but also a marked decrease in
unspliced viral RNA abundance leading to a loss of
virus replication [17]. Similarly, mutations in Env have
been identified that activate a cryptic splice through
recruitment of the SR protein SRSF2 (SC35) and hnRNP
H [18]. In addition, overexpression of the SR protein
SRSF1(SF2/ASF) has been shown to increase use of the
3’ss for Vpr (SA2) while increased levels of SRSF2/
SRFS7 (9G8) induce use of the 3’ss for Tat (SA3)
[19-21].
The sensitivity of HIV-1 RNA processing to changes in
abundance or activity of SR proteins has suggested that
these factors could be targeted to achieve changes in the
nature and/or extent of viral RNA splicing so as to inhibit
HIV-1 replication. Support for this hypothesis can be
found in the observation that HIV-1 infection is asso-
ciated with changes in SR protein phosphorylation/abun-
dance that could be reversed upon overexpression of SR
protein kinase 2 (SRPK2) [22-24]. Several proteins have
been shown to phosphorylate SR proteins, with members
of the SR protein kinase (SRPK1 and SRPK2) and Cdc2
like kinase (CLK1, CLK2, CLK3 and CLK4) families
being the most intensively studied [25]. Comparison of
SRPK and CLK kinases have revealed that, while both
can phosphorylate SR proteins, they differ in the extent
of phosphorylation and in the protein sequences modi-
fied [26-29]. This fact, coupled with differences in subcel-
lular localization (SRPKs are cytoplasmic while CLKs are
nuclear), suggests that they play distinct roles in regulat-
ing SR protein activity [30-33].To explore the role of SR
kinases other than SRPK2 in regulating HIV-1 gene
expression, we examined the impact of overexpressing
members of the CLK family on viral RNA abundance and
protein synthesis. The four members of the CLK family
(CLK1/Sty, CLK2, CLK3 and CLK4) have overlapping
specificity for the phosphorylation of specific SR proteins
[25]. Despite a significant degree of homology between
the various CLK members, we observed that they had
disparate effects on HIV-1 expression; CLK1 promoting
expression of HIV-1 Gag while CLK2 dramatically sup-
pressed synthesis of viral structural proteins. Effects at
the protein level were mirrored in alterations in viral
RNA abundance, suggesting that CLK1 and CLK2 act to
modulate HIV-1 RNA processing in distinct ways. Based
on these observations, we also explored the effects of
recently described CLK inhibitors (TG003, chlorhexidine)
on HIV-1 replication [34,35]. Similar to the results with
the individual CLKs, we observed that the two inhibitors
had markedly different effects on viral gene expression:
TG003 treatment had no effect while chlorhexidine sig-
nificantly suppressed HIV-1 Gag synthesis. In context of
HIV-1 growth in PBMCs, chlorhexidine also suppressed
virus replication. Given that chlorhexidine is currently
used in humans at doses ~1000 fold greater than used in
our assays, our findings suggest that this compound
could be used at mucosal surfaces to prevent virus
transmission.
Results
CLK1 Increases While CLK2 Decreases HIV-1 Gene
Expression
Multiple cellular kinases have been implicated in the
phosphorylation of SR proteins, a modification critical
to their function in RNA splicing [33,36-40]. To explore
the potential roles of the members of the Cdc2-like
kinase (CLK) family in the regulation of HIV-1 RNA
processing and expression, GFP-tagged expression vec-
tors for each of the CLKs were transfected into cells
carrying an integrated, doxycycline-inducible form of
HIV-1 (see additional file 1, Figure S1). As shown in
Figure 1, the CLKs are a highly related family of pro-
teins with CLK1 and CLK4 displaying the highest degree
of similarity [26]. Subsequent analysis of cell lysates con-
firmed expression of each of the CLKs in this cell sys-
tem (Figure 1D). Parallel examination of the effect of
CLK overexpression on SRSF2 (SC35) subcellular distri-
bution confirmed, as previously documented, that all of
these factors disrupted SRSF2 subnuclear distribution
from being primarily confined to nuclear speckles to
being dispersed throughout the nucleus (Figure 2) as a
result of the hyperphosphorylation of the protein
[31,32,36].
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CLK overexpression on virus replication, was generated
by stable insertion of an HIV-1 provirus whose expres-
sion from the TetON promoter, within the viral LTR, is
dependent on addition of doxycycline to activate the
endogenous TetO transactivator (rtTA) or transfection
with the constitutively active TetO transcriptional acti-
vator (tTA) [41,42] (see additional file 1, Figure S1). As
shown in Figures 3A and 3B, cells transfected without
the tTA activator did not express any HIV-1 Gag (p24)
over background. Comparison of HIV-1 Gag expression
of cells transfected with the various CLKs versus control
vector revealed marked differences in response. Expres-
sion of GFP-CLK1 was observed to induce a ~3 fold
increase in HIV-1 Gag expression while CLK 2 reduced
synthesis of the same viral protein by ~4 fold. CLK3
and CLK4 overexpression had only modest effects.
Expression of a catalytically inactive form of CLK2
Figure 1 Analysis of CLK Homology and Expression. Sequence alignment of CLK 1, 2, 3 and 4 indicating the degree of homology among
these factors. Also shown are the % sequence identity (B) and sequence similarity (C) among the four kinases. (D) Cells were transfected with a
control plasmid (control) or vectors expressing GFP-CLK1 (mCLK1), GFP-CLK2 (mCLK2), GFP-CLK3 (mCLK3), or GFP-CLK4 (mCLK4). Forty-eight
hours post-transfection, cells were harvested and extracts fractionated on SDS-PAGE gels. Resultant blots were probed first with anti-GFP
antibody to detect individual CLKs then with anti-tubulin antibody to confirm equal loading of samples.
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this system consistent with it having a transdominant
effect. Subsequent experiments determined that inhibi-
tion of HIV-1 was correlated with the level of CLK2
overexpression (Figure 3C). To explore the basis for the
observed responses, total RNA was isolated from the
cells and the abundance of HIV-1 unspliced (US), singly
spliced (SS) and multiply spliced (MS) RNAs determined
by qRT-PCR. As shown in Figure 4A, changes in viral
G a ge x p r e s s i o ni nr e s p o n s et ot h ev a r i o u sC L K sc o r r e -
lated with changes in abundance of the respective
mRNA: CLK1 overexpression increasing HIV-1 US RNA
~2 fold while CLK2 reduced accumulation of all HIV-1
RNAs by ~5 fold. CLK3 and CLK4 were observed to
have more moderate effects on HIV-1 gene expression
and viral RNA abundance. To assess whether CLK over-
expression was also associated with any alterations in
splice site selection, a radioactive RT-PCR was per-
formed on the MS class of viral RNAs that detects the
complete spectrum of MS RNA products generated (Fig-
ure 4B). These experiments revealed only subtle changes
in relative abundance of MS RNA products in the pre-
sence of CLK2. Consequently, although CLK1 and
Figure 2 Effect of CLK Overexpression on SRSF2 (SC35)
Subcellular Distribution. Cells were transfected with GFP-CLK
expression vectors, incubated for forty-eight hours post-transfection, and
then fixed and processed for immunofluorescence localization of SRSF2.
Cells were stained with anti-SRSF2 antibody followed by Texas Red-
conjugated donkey anti-mouse antibody and nuclei stained with DAPI.
Shown are representative samples of the localization patterns of the
CLKs and SRSF2 observed from > 5 experiments. Magnification 630x.
Figure 3 Differential Effect of CLKs on HIV-1 Provirus
Expression. Cells were transfected with CMVmyc 3xTerm (-) or
CMVtTa (+, to induce endogenous HIV-1 provirus expression) along
with control plasmid (CMVmyc 3xterm) or vectors expressing GFP-
CLK1, GFP-CLK2, GFP-CLK3, GFP-CLK4, or the kinase-inactive form,
GFP-CLK2 KR. Forty-eight hours post-transfection, media and cells
were harvested and Gag (p24) protein levels determined by (A) p24
ELISA or (B) western blot. Shown are the averaged results of >5
independent assays with asterisks denoting results determined to
significantly different from control (+tTA) at a p value of < 0.05. (C)
As above but cells were transfected with increasing amounts of
CLK2 expression vector. Media was harvested two days post
transfection and HIV-1 Gag (p24) protein levels determined by
ELISA. Shown is the average of multiple independent trials (N = 3).
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accumulation, they do not cause a gross alteration in
use of any specific set of splice sites.
Chlorhexidine Inhibits CLK2, 3 and 4 Function and Alters
HIV-1 RNA Processing
Our demonstration that altering the relative levels of
CLKs has profound effects on HIV-1 gene expression
suggested that we might be able to produce similar
responses using CLK inhibitors. Recent work has identi-
fied two compounds that can alter the function of a
specific subset of CLKs: TG003 inhibits CLK1, CLK4,
and, to a lesser extent, CLK2, while chlorhexidine is an
inhibitor of CLK2, 3,.and 4 in vitro [34,35]. To verify
the activity of these compounds at doses used in subse-
quent assays, we examined their ability to suppress the
disruption of nuclear speckles upon CLK overexpression
by blocking hyperphosphorylation of SR proteins. As
shown in Figure 5A, treatment of cells with TG003 was
found to block disruption of nuclear speckles by CLK1,
2 and 4. In contrast, chlorhexidine prevented nuclear
speckle disruption upon overexpression of CLK2, 3 and
4 (Figure 5B). In the case of both TG003 and chlorhexi-
dine, drug treatment also resulted in movement of the
affected CLKs (with the exception of CLK3) to subnuc-
lear structures that partially overlap with nuclear speck-
les. An inactive analog of TG003 (TG009) was found to
have no effect (data not shown), confirming that the
response is attributable to specific effects of the inhibi-
tors and not the solvent on CLK activity [34]. These
observations confirm that TG003 and chlorhexidine
have overlapping but different target protein
specificities.
These compounds were subsequently evaluated for
their effect on HIV-1 gene expression. HeLa cells con-
taining the Tet-ON HIV-1 provirus were exposed to
compounds for 4-5 hours prior to induction of the pro-
virus by addition of doxycycline to the medium. Media,
RNA and protein were harvested 24 h later. As shown
in Figure 6A, neither TG003 nor TG009 had any sub-
stantial effect on induction of HIV-1 Gag protein, while
chlorhexidine caused a ~4 fold reduction in expression
of this viral protein. Evaluation of the dose-response
characteristics of chlorhexidine on HIV-1 gene expres-
sion determined that significant repression occurred at
doses of ~ 2.5 μM (Figure 6B). In contrast, examination
of cell viability following chlorhexidine treatment (Figure
6C) revealed little effect at doses required to suppress
virus replication in the time frame of the assay. Evalua-
tion of the effect of chlorhexidine on HIV-1 RNA levels
determined that it induced an alteration in viral RNA
abundance, decreasing US and SS RNA accumulation by
~60% while increasing levels of MS RNAs 1.6 fold (Fig-
ure 7A). Parallel examination of viral MS RNA splicing
patterns (Figure 7B, additional files 2 &3, Figure S2, 3)
determined that neither chlorhexidine nor TG003
induced any significant alteration in use of specific
splice sites within this MS class of HIV-1 RNAs.
Chlorhexidine Treatment Inhibits HIV-1 Rev Accumulation
In addition to the alteration in HIV-1 RNA levels that
could account for the loss of viral protein expression,
we examined whether chlorhexidine treatment changed
expression of any of the viral regulatory proteins such as
Tat or Rev. Since Tat is essential for optimal HIV-1
Figure 4 Differential Effect of CLK Overexpression on HIV-1
RNA Accumulation and Splicing. Cells were transfected with
CMVmyc 3xTerm (-) or CMVtTa (+, to induce provirus expression)
along with control plasmid (CMVmyc 3xterm) or vectors expressing
GFP-CLK1, GFP-CLK2, GFP-CLK3 or GFP-CLK4. Forty-eight hours post-
transfection, cells were harvested and total RNA extracted. (A)
Abundance of unspliced (US), singly spliced (SS), and multiply
spliced (MS) viral RNAs was determined by qRT-PCR as outlined in
“Materials & Methods”. Shown are the average of >7 independent
analyses. (B) To examine the effect of overexpression of individual
CLK proteins on viral RNA splicing, radioactive RT-PCR was
performed on MS viral RNAs. Products were fractionated on 8M
urea-PAGE gels and gels exposed to phosphor screens to detect the
different splice products. For explanation of the products generated,
please refer to additional file 2, Figure S2. On the left is a
representative RT-PCR gel of the pattern observed and on the right,
a summary of the relative abundance of each splice product
(fraction of total viral MS RNA) for >3 independent assays. Asterisks
denote values determined to be significantly different from control
at a p value < 0.05.
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incompletely spliced viral RNAs to the cytoplasm [4-7],
reduced expression of either or both would dramatically
alter expression of the HIV-1 provirus. Western blots of
extracts prepared from cells incubated in the presence
or absence of drug (TG009, chlorhexidine) were probed
to assess Tat and Rev expression. As shown in Figure 8,
treatment of cells with chlorhexidine resulted in a
marked reduction in Rev expression (to below the level
of detection) without affecting levels of Tat p16
(encoded by MS RNA). However, Tat p14 levels were
reduced upon chlorhexidine treatment. Since Rev is
required for nuclear export of all HIV-1 US and SS
RNAs, loss of Rev would be expected to reduce expres-
sion of all proteins encoded by this group of RNAs,
including Tat p14 (encoded by SS RNA). Therefore, the
observed changes in Tat expression can be directly
related to the effect of chlorhexidine on Rev.
Chlorhexidine is an Inhibitor of HIV-1 Replication in
PBMCs
Our observation that chlorhexidine can dramatically
reduce expression of the HIV-1 provirus in the TetON
HIV cell line suggested the exciting possibility that it
Figure 5 TG003 and Chlorhexidine Alter the Effect of CLK
Kinases on SRSF2 (SC35) Subcellular Distribution. Cells were
transfected with GFP-CLK expression vectors. Forty-eight hours post-
transfection, cells were treated with (A) 10 μM TG003 or (B) 10 μM
chlorhexidine for 4-5 h then fixed and processed for
immunofluorescence localization of SRSF2. Cells were stained with
anti-SRSF2 antibody followed by Texas Red conjugated donkey anti-
mouse antibody and nuclei stained with DAPI. Shown are
representative samples of the localization patterns of the CLKs and
SRSF2 observed. Magnification 630x.
Figure 6 Chlorhexidine is a Potent Inhibitor of HIV-1 Gene
Expression. (A) Cells were treated for 4-5 h with TG003, TG009 or
chlorhexidine, then doxycycline was added to induce expression of
the endogenous HIV-1 provirus. Twenty-four hours later, cell media
were harvested, and HIV-1 Gag (p24) protein levels determined by
ELISA. Shown are the average of >9 independent assays, asterisks
denoting results determined to significantly different from control
(DMSO +Dox.) at a p value < 0.01. (B) As described in A, but cells
were treated with varying doses of chlorhexidine to identify the
minimum dose required to suppress HIV-1 gene expression. (C) To
assess the effect of chlorhexidine on cell viability, cells were
incubated with indicated dose of chlorhexidine (0.5 - 10 μM) for 24
h then an XTT assay performed. Level of XTT conversion, which
measures the number and metabolic activity of the cells, was
compared to DMSO-treated cells.
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natural context, CD4+ T cells. To test this hypothesis,
PBMCs were infected with an R5 strain of HIV-1 (BaL)
and cells subsequently treated with a range of chlorhexi-
dine concentrations. Three and seven days post-infec-
tion, cell supernatants were harvested and levels of viral
production determined by p24 (Gag) ELISA. As shown
in Figure 9A and 9B, treatment of cells with doses of
chlorhexidine 2.5 μM or greater resulted in a marked
reduction in viral replication at both time points ana-
lyzed. Parallel measurement of cell viability over the
same time period (Figure 9C) determined that doses of
chlorhexidine required to suppress HIV-1 replication
resulted in some reduction in cell viability over the
course of this assay but not enough to account for the
loss of virus replication.
Discussion
Previous studies on the regulation of RNA processing
have clearly outlined the important role of SR proteins
in modulating usage of particular splicing sites [15].
Consequently, modulating RNA processing could be
achieved by either regulating the abundance of specific
SR proteins or modulating their activity through
changes in the extent of their phosphorylation [43,44].
Either hyper- or hypo-phosphorylation of SR proteins
has been shown to alter their ability to support RNA
splicing in vitro and results in changes in alternative
splicing choices [25-33,45]. Previous analysis of the role
played by SRPK2 in controlling HIV-1 gene expression
determined that its overexpression increased virus pro-
duction putatively by modulating the activity of SRp75
[22]. Our findings on the effect of CLK overexpression
on HIV-1 replication revealed that overexpression of
individual CLKs had very distinct effects on HIV-1 RNA
processing and gene expression. This point is best illu-
strated by comparison of CLK1 with CLK2. While CLK1
overexpression resulted in increased HIV-1 Gag RNA
levels and protein synthesis, CLK2 overexpression led to
dramatic suppression of HIV-1 Gag production asso-
ciated with reduced accumulation of all viral RNAs (US,
SS and MS). Differences between the various CLKs
occurred despite comparable expression and their indis-
tinguishable effects on SRSF2 subnuclear distribution
(Figures 1 and 2). Previous analyses had demonstrated
that altering CLK expression levels modified a number
of alternative splicing events but, in most instances,
changing expression of different CLKs had the same
Figure 7 Effect of Chlorhexidine on HIV-1 RNA Accumulation
and Splicing. Cells were treated for 4-5 h with TG003, TG009 or
chlorhexidine (5 μM), then doxycycline was added to induce
expression of the endogenous HIV-1 provirus. Twenty-four hours
later, cells were harvested and total RNA extracted. (A) Abundance of
US, SS, and MS viral RNAs was determined by qRT-PCR as outlined in
“Materials & Methods”. Shown are the average of >5 independent
analyses. (B) To examine the effect of drug treatment on viral RNA
splicing, radioactive RT-PCR was performed on MS viral RNAs and
products fractionated on 8 M urea-PAGE gels followed by exposure
to phosphor screens to detect the different splice products. On the
left is a representative gel of the pattern observed and on the right, a
summary of the relative abundance of each splice product over
multiple assays (n > 6). Asterisks denote values determined to be
significantly different from control at a p value < 0.05.
Figure 8 Chlorhexidine Reduces Expression of HIV-1 Rev. Cells
were untreated or treated for 4-5 h with TG009 or chlorhexidine,
then expression of the endogenous HIV-1 provirus was induce by
addition of doxycycline. Twenty-four hours later, cells were
harvested and cell extracts fractionated on SDS-PAGE gels. Resultant
blots generated were probed with anti-Rev, anti-Tat or anti-tubulin
antibodies to assess the effect of drugs on viral protein expression.
Results shown are representative of >3 independent trials.
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[46-48]. Consequently, our observation of marked differ-
ences in effect of individual CLKs on HIV-1 is one of
the first demonstrations of distinct activities between
these individual family members. The contrasting effects
of CLK2 versus the kinase inactive CLK2 KR (acting as
ad o m i n a n tn e g a t i v e )o nH I V - 1e x p r e s s i o nc o n f i r mt h a t
the effects observed are due to kinase activity and not
simply overexpression of the protein.
The basis for the differences between the various
CLKs is presently unclear. Preliminary analysis of
changes in SR protein phosphorylation upon overexpres-
sion of different CLKs revealed increased levels of SR
protein phosphorylation but no differences in the SR
proteins modified (data not shown). Consequently, dif-
ferences may reflect differing extents of phosphorylation
or modifications of specific residues within SR proteins.
Alternatively, given that CLKs have been shown to
interact with proteins outside of the SR protein family,
the different activities could reflect phosphorylation of
other host factors [36,49-52].
Similar to the differential responses to the overexpres-
sion of individual CLKs, the two CLK inhibitors tested
also yielded very distinct effects. TG003 inhibits predo-
minately CLK1 and CLK4, with reduced effect on CLK2
but had little to no effect on HIV-1 gene expression. In
contrast, chlorhexidine, which blocked HIV-1 Gag and
Rev synthesis, is a potent inhibitor of CLK3 and 4 with
reduced activity against CLK2 as measured by its capa-
city to reverse CLK-induced effects on SRSF2 subnuc-
lear distribution [35]. The fact that both drugs have
overlapping activity against the various CLKs but yield
strikingly different effects on virus expression suggests
that the regulation of HIV-1 is due to the effect of
chlorhexidine on CLK3 function alone, alterations in the
relative activities of the individual CLKs present, or pos-
sibly modulation of another host factor. Altering relative
activities among the individual CLKs by overexpression
or drug inhibition could account for the inhibitory
effects on HIV-1 gene expression.
Subsequent evaluation of the basis for chlorhexidine
suppression of HIV-1 gene expression/replication indi-
cated that the response is distinct from that seen upon
overexpression of CLK2 or 3, as indicated by their
effects on viral RNA accumulation. CLK3 overexpres-
s i o nh a dal i m i t e de f f e c to nv i r a lR N Aa b u n d a n c ea n d
CLK2 overexpression repressed accumulation of all
HIV-1 RNAs. In contrast, chlorhexidine induced a shift
in viral RNA accumulation, reducing levels of US and
SS RNAs while increasing MS RNA levels. Such a
response is suggestive of an enhancement of the overall
splicing of HIV-1 RNAs given that subsequent analysis
did not detect any shift in splice site usage. In addition,
chlorhexidine selectively reduced Rev protein expression
without any change in Tat (p16) levels. In the absence
of any reduction in Rev RNA abundance, it would
appear that chlorhexidine also selectively inhibits Rev
RNA translation or reduces the stability of this protein.
Whatever the mechanism, the reduced levels of Rev
account for the loss of p24 (Gag) seen since Rev is
Figure 9 Chlorhexidine Inhibits HIV-1 Replication in PBMCs.T o
assess the effect of chlorhexidine on HIV-1 replication, PBMCs were
infected with the BaL strain of HIV-1 for 2 h. Subsequently, varying
doses of chlorhexidine (0.5-5 μM) were added to the medium.
Medium -/+ drug was harvested (A) 3 and (B) 7 days post-infection
and level of virus production determined by p24 ELISA. (C) The
effect of chlorhexidine treatment on PBMC viability was monitored
by trypan blue exclusion on days 3 and 7 post HIV-1 infection.
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sponding viral US and SS RNAs.
Conclusions
In summary, our experiments have highlighted the dif-
ferent activities among members of the CLK family in
the regulation of HIV-1 gene expression and RNA pro-
cessing. This finding suggests that these kinases likely
selectively modulate alternative RNA splicing in the
context of other genes. More significantly, we have
demonstrated that small molecule inhibitors of specific
CLKs can suppress HIV-1 gene expression and replica-
tion. Given that the process affected by chlorhexidine is
distinct from those targeted by current HIV-1 therapeu-
tics (i.e. entry, reverse transcription, integration, virus
maturation), these findings highlight the feasibility of
targeting viral RNA processing as a novel strategy to
control HIV-1 replication that could be used in concert
with current drug combinations to enhance the control
of this infection [53]. Chlorhexidine is already in use in
humans as the active ingredient in mouthwash and topi-
cal antiseptics at doses (~2 mM) 1000 fold above those
required to block HIV-1 replication. While the observed
toxicity of chlorhexidine in the context of PBMCs pre-
cludes its systemic use, its application on mucosal sur-
faces is well tolerated in humans suggesting the use of
chlorhexidine as a microbicide to block HIV-1 transmis-
sion at the site of entry (mucosal surfaces) by inhibiting
virus replication in the local region or reducing the level
of virus secretion at these surfaces in those already
infected. A better understanding of the mechanism of
chlorhexidine/CLK2 action will likely provide greater
insights that could guide the development of additional
compounds with improved specificity and activity.
Materials and methods
Plasmids and cell tranfections
To explore the effects of CLKs on HIV-1 protein
expression/RNA, HeLa cells stably transduced with an
inducible Tet-On HIV-1 system were used [41,42]. Acti-
vation of HIV-1 gene expression was achieved by either
addition of doxycyline (Dox) at a concentration of 2 μg/
ml or transfection with the constitutively active Tet acti-
vator, tTA. Modification of the published HIV Tet-ON
system consisted of deleting the RT and IN genes by
Mls1 digestion and using the resulting construct to gen-
erate the HeLa rtTA HIVΔm l sc e l ll i n eb yr e t r o v i r a l
transduction and cloning (Figure S1). To explore the
effect of CLK overexpression on HIV-1 gene expression,
cells were transfected with empty expression plasmid
(CMVmyc 3xterm) or vectors expressing GFP-CLK1,
GFP-CLK2, GFP-CLK3, GFP-CLK4 (provided by J. Bell,
University of Ottawa) or GFP-CLK2 KR (provided by S.
Stamm, University of Kentucky) along with CMVtTA to
induce provirus expression in cells taking up DNA.
Transfections were performed using polyethylene imine
(PEI, Polysciences Inc.). Cells and media were harvested
48 h post-transfection to assess effects on HIV-1 gene
expression.
In the case of drug treatment, cells were seeded onto
6-well plates at approximately 0.5 × 10
6 cells per well
(~50-75% confluence) in IMDM with 10% FBS and anti-
biotics (1 × Pen-Strep, 100 μg/mL, 1 × Amphotericin B,
0.5 μg/mL) (Wisent Corporation). Drugs were obtained
from Sigma-Aldrich (Chlorhexidine, cat. #C6143)) or
provided by Masatoshi Hagiwara (TG003/TG009, Tokyo
Medical & Dental University) and solubilized to 10 mM
with DMSO. After 4-5 hours of drug treatment, HIV
expression was induced by addition of doxycycline (2
μg/ml final concentration). After approximately 24
hours, cell supernatants were harvested for p24 ELISA,
while cells were harvested for RNA or protein analyses.
Cell viability was monitored by either trypan blue exclu-
sion (Gibco) or XTT assay (Sigma-Aldrich) [54].
Analysis of HIV-1 protein expression
For analysis of HIV-1 (Gag) protein expression, media
was adjusted to 1% Triton X-100 and assayed by p24
ELISA as described in the HIV-1 p24
CA antigen capture
assay kit (AIDS & Cancer virus Program, NCI-Frederick,
Frederick, MD, USA).
Quantitation of HIV-1 mRNA Levels
Cells were harvested by incubation in 2 mM EDTA-PBS
for 15 minutes at 37°C and pelleted cells used in RNA
purification or protein analysis. RNA was purified by
Aurum Total RNA Mini Kits (Bio-Rad, Cat. #732-6820).
Purified RNA was reverse transcribed using M-MLV
(Invitrogen, Cat. #28025-013). cDNAs reactions (20 μl)
were diluted to 150 μL and used in qRT-PCR analysis of
HIV-1 mRNA levels using the standard curve method.
Each reaction was set-up as follows: 0.4 μL of Taq DNA
polymerase (5 U/μL, NEB, Cat. #M0267L), 2.5 μLo f
ThermolPol buffer, 2.5 μL of 10X SYBR Green I
(Sigma-Aldrich, Cat. #S9430), 2.5 μL of 2.5 mM dNTPs,
1.0 μLo f5 ’ primer (0.1 ug/uL), and 1.0 μLo f3 ’ primer
(0.1 μg/μL), 10.1 μLH 2O, and 5 μLo fc D N A .T h ef o r -
ward and reverse primers used in the quantitation of
HIV-1 mRNA are shown below: unspliced (US), 5’ -
G A CG C TC T CG C AC C CA T CT C-3 ’ and 5’ -C T G
AAG CGC GCA CGG CAA - 3’; singly spliced (SS), 5’ -
GGC GGC GAC TGG AAG AAG C - 3’ and 5’ -C T A
TGA TTA CTA TGG ACC ACA C - 3’; and multiply
spliced (MS), 5’ - GAC TCA TCA AGT TTC TCT
ATC AAA - 3’ and 5’ - AGT CTC TCA AGC GGT
GGT - 3’. Results were normalized to the housekeeping
gene, ß-actin, which served as an internal loading con-
trol. 5’-GAGCGGTTCCGCT GCCCTGAGGCACTC-3’
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qRT-PCRs were run on an Eppendorf Mastercycler ep
realplex
4. The cycle conditions used for US, MS, and
Actin were 95°C, 2 min followed by 40 cycles of 95°C,
1 5 s ;6 0 ° C ,1 5 s ;a n d7 2 ° C ,1 5 s .S Sc o n d i t i o n sw e r e9 5 ° C ,
2 min followed by 40 cycles of 95°C, 30s; 55°C, 30s; and
72°C, 30s.
Analysis of HIV-1 alternative splicing
The effect of CLKs and drugs on HIV-1 splice site usage
was performed as previously described [55]. cDNAs
were analyzed for changes in splice site usage within the
2 kb, MS RNA class. The forward and reverse primers
are as followed: 5’-GGGCAGTGATCTCCTTCTG-
CATCCTG -3’ and 5’ -TCA TTG CCA CTG TCT TCT
G C TC T-3 ’. Initial rounds of cold RT-PCR were set-
up as followed: 1 μL cDNA, 1 μL of Taq DNA polymer-
ase, 5 μL of 10X ThermolPol buffer, 4 μLo f2 . 5m M
dNTPs, 10 μLo ff o r w a r dp r i m e r( 1 0μM), 10 μLo f
reverse primer (10 μM), and 19 μLo fH 2Oi na5 0μL
final reaction volume. Thermocycler conditions used
were 95°C, 2 min followed by 34 cycles of 95°C, 1 min;
57°C, 1 min; and 68°C, 1 min; and ended with 68°C, 5
min; and 4°C, indefinitely. A second round of radioac-
tive PCR was run with the following changes/additions
to the conditions described above: 3 μLo fd i l u t e d
cDNA from the first PCR reaction (1/10
th dilution), 0.5
μLo fa-
32P-dCTP (Perkin Elmer, #BLU013A250UC),
and 16.5 μLo fH 2O. The same thermocycler conditions
were also used except only 5 cycles were run. An equal
volume of loading buffer (90% formamide, 10 mM
EDTA, 0.025% xylene cyanol, and 0.025% bromophenol
blue) was added to the products and heated at 95°C for
5 minutes prior to loading onto sequencing gels (6%
polyacrylamide, 8 M Urea, 1xTBE), and products
detected by phosphoimager. Densitometry was per-
formed using ImageJ by density plots generated for each
lane. Values for each HIV-1 RNA specie(s) detected
were divided by the total density from all viral RNA spe-
cies in a sample (fraction of total RNA).
Western blot analysis of HIV-1 proteins
Cells pellets were solubilized in 100 to 300 uL of RIPA
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS), incubated at
95°C for 5 minutes, and centrifuged for 2 minutes at 12
K × g. Lysate supernatants were quantitated by Bradford
assay. For Western blotting, equal amounts of protein
were run on 7, 10 or 12% SDS-PAGE, transferred to
PVDF (0.45 μm, Perkin-Elmer, Cat. #NEF1002) by elec-
trophoretic transfer and blots blocked in 5% Milk-PBS-
T (0.05% Tween-20, 1xPBS) for 1 h at room tempera-
ture. For Rev, blots were probed with a 1/250 dilution
of mouse monoclonal (Rev-6) antibody to HIV-1 Rev
( A b c a m ,C a t .# a b 8 5 5 2 9 )i nP B S - T .F o ra-Tubulin, blots
were washed then probed with mouse monoclonal a-
Tubulin antibody (Sigma-Aldrich, Cat. #T9026) diluted
to 1/5000 in PBS-T. For Tat, blots were probed with a
1/5000 dilution of rabbit polyclonal antibody to HIV-1
Tat (Abcam, Cat. #ab43014) in 5% Milk-PBS-T. After
primary antibody incubations, blots were washed in
PBS-T and then incubated with a 1/5000 dilution of iso-
type-specific HRP-conjugated secondary antibody in 5%
Milk-PBS-T available from Jackson ImmunoResearch
(Cat. #715-036-150 for rabbit and Cat. #711-036-152 for
mouse). After washes, blots were developed using Wes-
tern Lightning ECL (Perkin-Elmer, Cat. #NEL101) and
exposed to autoradiography film.
Effect of drugs on CLK kinase modulation of SR protein
subnuclear distribution
Cells were transfected with vectors expressing GFP-
tagged CLK1, CLK2, CLK3 or CLK4. Two days post-
transfection, cells were either treated with DMSO,
TG003 or chlorhexidine for 4-5 h or overnight prior to
fixation in 4% paraformaldehyde, 1xPBS. Cells were sub-
sequently permeabilized by treatment with 1% Triton X-
100, 1xPBS followed by blocking in 3% BSA, 1xPBS for
1 h. Subcellular distribution of SRSF2 (SC35) was deter-
mined by staining with a mouse anti-SRSF2 (SC35) anti-
body (BD Sciences) followed by incubation with a Texas
Red-labeled donkey anti-mouse antibody (Jackson
Immunoresearch). Cells were stained with DAPI prior
to mounting to detect nuclei. Images were captured
using a Leica DMR microscope.
HIV-1 infection of PBMCs
Blood was isolated from HIV seronegative donors, leu-
kapheresed, and stored at -80°C. PBMCs were isolated
from blood of healthy donors using Ficoll-Hypaque
(VWR, Cat. #CA95038-170L as detailed by manufac-
turer. For infections, 1 mL of cells (100 × 10
6)w e r e
thawed, diluted in R-2 (RPMI containing 2% FBS) and
centrifuged at 300 RCF for 10 minutes at room tem-
perature. Thawed cells were cultured at 37°C in R-10 or
RPMI complete medium (10% FBS (heat-inactivated),
1% GlutaMAX-1 (Invitrogen, Gibco, Cat. #35050-061),
1x Pen-Strep (100 μg/mL; Wisent Corp.), and 1 ×
Amphotericin B (0.5 μg/mL; Wisent Corp.), containing
2 μg/mL of PHA-L (Sigma, Cat. #L2769) and 20 U/mL
of IL-2 (BD Pharmingen, Cat. #554603). After 48 h,
PBMCs were isolated by Ficoll-Hypaque density gradient
centrifugation, washed with R-2 medium, and centri-
fuged at 450 RCF for 25 min. to remove dead cells.
Next, cells from each donor were resuspended in R-10
with 20 U/mL of IL-2 and infected with a R5 HIV-1
strain (BaL) at an MOI of 10
-2. After 2 h of infection at
37°C, cells were washed 3 times with R-2. Cell pellets
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Page 10 of 12were resuspended in R-10 with 20 U/mL of IL-2, seeded
at 2 × 10
6 cells per well in 24-well plates, and treated
with drugs at the indicated doses. Media were harvested
every 2 or 3 days after infection and assayed by p24
ELISA as described. The effect of these drugs on cell
viability was assessed by trypan blue stain and counted
on Kova Glasstic slide 10 with grids (VWR, Cat.
#CA36200-020).
Additional material
Additional file 1: Figure S1. Characterization of HeLa HIVrtTA ΔMLS
Cell Line. (A) Outline of the HIV-1 proviral construct used to generate
cell line. Provirus has insertion of TetO operator sites in the U3 region,
substitution of Nef with the doxycyclline-dependent transactivator rtTA,
mutational inactivaion of Tat and TAR and deletion of the RT and IN
reading frames. HeLa cells were transduced and screened for doxycycline
dependent expression of the HIV-1 structural proteins. (B) Cells were
incubated in the presence or absence of doxycycline (Dox), fixed with
paraformaldehyde then Gag protein expression detected using anti-Gag
antibodies. (C-E) Following incubation for 24 h in the presence or
absence of doxycycline, cells were harvested for RNA (C) or protein (D, E)
extracted and fractionated on gels. (C) Following transfer to
nitrocellulose, northern blots were probed with radioalabelled probe to
the HIV-1 LTR (allowing detection of HIV-1 US, SS and MS RNAs) or
endogenous GAPDH RNA. (D,E) Proteins were fractionated on SDS-PAGE
gels, blotted, and blots probed with antibodies against HIV-1 Gag (p55.
p41, p24), Env (gp160, gp120), Tat (p16, p14), or Rev (p19). To confirm
equivalent loading, blots were also probed with antibody to a-tubulin
(Tub). In (D), cells were treated with doxycycline or transfected with
plasmid encoding the doxycycline-independent transactivator, tTA.
Additional file 2: Figure S2. Outline of HIV-1 RNA Alternative
Splicing Shown at the top is the organization of the HIV-1 proviral
genome, indicating the position of the multiple 5’ splice sites (SD1 to
SD4) and 3’ splice sites (SA1 to SA7) used. Below is an illustration of the
spliced RNAs generated by processing of the HIV-1 genomic RNA.
Indicated are the common (open boxes) and alternative (closed boxes)
exons used in the generation of the SS (4 kb) and MS (1.8 kb) viral RNAs.
At the bottom, is the nomenclature used in reference to the exon
composition of the individual RNAs generated for both the SS and MS
classes of HIV-1 RNAs.
Additional file 3: Figure S3. Effect of TG003 and TG009 on HIV-1
RNA Splicing To examine the effect of drug treatment on viral RNA
splicing, radioactive RT-PCR was performed for MS viral RNAs and
products fractionated on 8 M urea-PAGE gels followed by exposure to
phosphor screens to detect the different splice products. Shown is a
summary of the relative abundance of each splice product over multiple
assays relative to untreated (control) cells.
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